301015.SZ
301015.SZ
CNE100004LR8
BAHEAL MEDICAL
Loading chart...

Company Profile

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and internationally. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; and liver disease drugs under the Fuzhenghuayu brand name. It also provides tumor and other severe drugs under the Utidelon, Gore Ning, Mai Ruibei, and Hai Ruisi brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; and medical nutrition under the Nutrasumma brand name, as well as skincare under the Cactus brand name. In addition, the company offers ZAP-X, an AI radiosurgery robot for intracranial tumors and lesions; Cifu VAD, the fully magnetically levitated ventricular assist device; and AtriCure Bipolar Radiofrequency Ablation Isolator for the treatment of chronic atrial fibrillation. The company was incorporated in 2005 and is based in Qingdao, China. Qingdao Baheal Medical INC. is a subsidiary of Baiyang Pharmaceutical Group Co., Ltd.

Related stocks

600056.SS
600056.SS • China
CHINA MEHECO GROUP CO LTD
9.14 CNY
2.05B USD 1Y -19.3%
000028.SZ
000028.SZ • China
SINOPHARM ACCORD
19.96 CNY
1.83B USD 1Y -13.1%
0874.HK
0874.HK • China
BAIYUNSHAN PH
13.21 HKD
2.74B USD 1Y -27.9%
600511.SS
600511.SS • China
CHINA NATIONAL MEDICINES CORP
26.67 CNY
3.01B USD 1Y -7.4%
000950.SZ
000950.SZ • China
CQP
5.34 CNY
1.37B USD 1Y +3.5%
600998.SS
600998.SS • China
JOINTOWN PHARMACEUTICAL GROUP C
5.08 CNY
3.83B USD 1Y +3.3%
600739.SS
600739.SS • China
LIAONING CHENGDA
10.33 CNY
2.35B USD 1Y -17%
600332.SS
600332.SS • China
GUANGZHOU BAIYUNSHAN PHARMACEUT
19.97 CNY
4.86B USD 1Y -22.1%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
47.3% p.a.
Max Drawdown (5Y)
-56.5%
Sharpe Ratio (5Y)
-0.10
Beta Factor
0.20
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (47.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -56.5% in the extended horizon.
ende